Author: "Cellini, Francesco (ORCID:0000-0002-2145-2300)" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Cellini, Francesco (ORCID:0000-0002-2145-2300)"' showing total 47 results

Start Over Author "Cellini, Francesco (ORCID:0000-0002-2145-2300)"

47 results on '"Cellini, Francesco (ORCID:0000-0002-2145-2300)"'

1. Editorial: How intravascular brachytherapy can turn to a renaissance due to high quality assurance in radiotherapy?

Author: Kovács, György, Cellini, Francesco, Trani, Carlo, Tagliaferri, Luca, Cellini, Francesco (ORCID:0000-0002-2145-2300), Trani, Carlo (ORCID:0000-0001-9777-013X), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Kovács, György, Cellini, Francesco, Trani, Carlo, Tagliaferri, Luca, Cellini, Francesco (ORCID:0000-0002-2145-2300), Trani, Carlo (ORCID:0000-0001-9777-013X), and Tagliaferri, Luca (ORCID:0000-0003-2308-0982)
Abstract: N/A
Published: 2023

2. Prognostic Score in Radiotherapy Practice for Palliative Treatments (PROPHET) Study for Bone Metastases: An Investigation Into the Clinical Effect on Treatment Prescription

Author: Cellini, Francesco, Di Rito, Alessia, Siepe, Giambattista, Pastore, Francesco, Lattanzi, Elisabetta, Meaglia, Ilaria, Tozzi, Angelo, Manfrida, Stefania, Longo, Silvia, Saldi, Simonetta, Cassese, Raffaele, Arcidiacono, Fabio, Fiore, Michele, Masiello, Valeria, Mazzarella, Ciro, Diroma, Antonio, Miccichè, Francesco, Maurizi, Francesca, Dominici, Luca, Scorsetti, Marta, Santarelli, Mario, Fusco, Vincenzo, Aristei, Cynthia, Deodato, Francesco, Gambacorta, Maria Antonietta, Maranzano, Ernesto, Muto, Paolo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Marino, Lorenza, Donati, Costanza M, Di Franco, Rossella, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria A (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Morganti, Alessio G, Cellini, Francesco, Di Rito, Alessia, Siepe, Giambattista, Pastore, Francesco, Lattanzi, Elisabetta, Meaglia, Ilaria, Tozzi, Angelo, Manfrida, Stefania, Longo, Silvia, Saldi, Simonetta, Cassese, Raffaele, Arcidiacono, Fabio, Fiore, Michele, Masiello, Valeria, Mazzarella, Ciro, Diroma, Antonio, Miccichè, Francesco, Maurizi, Francesca, Dominici, Luca, Scorsetti, Marta, Santarelli, Mario, Fusco, Vincenzo, Aristei, Cynthia, Deodato, Francesco, Gambacorta, Maria Antonietta, Maranzano, Ernesto, Muto, Paolo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Marino, Lorenza, Donati, Costanza M, Di Franco, Rossella, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria A (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Morganti, Alessio G
Abstract: Purpose: Bone metastases frequently occur during malignant disease. Palliative radiation therapy (PRT) is a crucial part of palliative care because it can relieve pain and improve patients' quality of life. Often, a clinician's survival estimation is too optimistic. Prognostic scores (PSs) can help clinicians tailor PRT indications to avoid over- or undertreatment. Although the PS is supposed to aid radiation oncologists (ROs) in palliative-care scenarios, it is unclear what type of support, and to what extent, could impact daily clinical practice. Methods and materials: A national-based investigation of the prescriptive decisions on simulated clinical cases was performed in Italy. Nine clinical cases from real-world clinical practice were selected for this study. Each case description contained complete information regarding the parameters defining the prognosis class according to the PS (in particular, the Mizumoto Prognostic Score, a validated PS available in literature and already applied in some clinical trials). Each case description contained complete information regarding the parameters defining the prognosis class according to the PS. ROs were interviewed through questionnaires, each comprising the same 3 questions per clinical case, asking (1) the prescription after detailing the clinical case features but not the PS prognostic class definition; (2) whether the RO wanted to change the prescription once the PS prognostic class definition was revealed; and (3) in case of a change of the prescription, a new prescriptive option. Three RO categories were defined: dedicated to PRT (RO-d), nondedicated to PRT (RO-nd), and resident in training (IT). Interviewed ROs were distributed among different regions of the country. Results: Conversion rates, agreements, and prescription trends were investigated. The PS determined a statistically significant 11.12% of prescription conversion among ROs. The conversion was higher for the residents and significantly higher for w
Published: 2023

3. Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients

Author: Rossi, Ernesto, Cellini, Francesco, Pagliara, Monica Maria, Sammarco, Maria Grazia, Pedone, Romina Rose, Lancellotta, Valentina, Tagliaferri, Luca, Quirino, Michela, Gambacorta, Maria Antonietta, Blasi, Maria Antonietta, Tortora, Giampaolo, Schinzari, Giovanni, Cellini, Francesco (ORCID:0000-0002-2145-2300), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Blasi, Maria Antonietta (ORCID:0000-0001-7393-7644), Tortora, Giampaolo (ORCID:0000-0002-1378-4962), Schinzari, Giovanni (ORCID:0000-0001-6105-7252), Rossi, Ernesto, Cellini, Francesco, Pagliara, Monica Maria, Sammarco, Maria Grazia, Pedone, Romina Rose, Lancellotta, Valentina, Tagliaferri, Luca, Quirino, Michela, Gambacorta, Maria Antonietta, Blasi, Maria Antonietta, Tortora, Giampaolo, Schinzari, Giovanni, Cellini, Francesco (ORCID:0000-0002-2145-2300), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Blasi, Maria Antonietta (ORCID:0000-0001-7393-7644), Tortora, Giampaolo (ORCID:0000-0002-1378-4962), and Schinzari, Giovanni (ORCID:0000-0001-6105-7252)
Abstract: Uveal melanoma is the most common ocular tumor with frequent metastatic spread to the liver. Immune checkpoint inhibitors have demonstrated poor results in this disease. The addition of hepatic radiotherapy to anti-PD-1 could enhance the sensitivity to immunotherapy. In this study, patients treated with pembrolizumab and who have undergone hepatic radiotherapy have been retrospectively evaluated. Twenty-two patients have been considered. Six patients (27.3%) achieved a partial response and 3 (13.6%) a stable disease. Disease control rate was 40.9%. Thirteen patients (59.1%) had progression as best response. The median PFS was 4.8 months and 6 months PFS rate 45.4%. The median OS was 21.2 months, while 1 year OS rate was 72.7%. Longer survival was observed in patients who achieved a partial response on irradiated metastases (HR 0.23, 95% CI 0.06-0.83) or progressed after 6 months (HR 0.12-95% CI 0.03-0.44). No radiotherapy-related or grade 3-4 adverse events were reported. This study demonstrates that the addition of hepatic radiotherapy to anti-PD-1 treatment can be a valid option for the treatment of metastatic uveal melanoma, particularly for HLA A 02:01 negative patients. Prospective studies should be conducted to confirm these data.
Published: 2023

4. Ventricular tachycardia ablation through radiation therapy (VT-ART) consortium: Concept description of an observational multicentric trial via matched pair analysis

Author: Cellini, Francesco, Narducci, Maria Lucia, Pavone, Chiara, Bencardino, Gianluigi, Perna, Francesco, Pinnacchio, Gaetano, Chiesa, Silvia, Massaccesi, Mariangela, Gambacorta, Maria Antonietta, Manfrida, Stefania, Longo, Silvia, Mannocci, Alice, Di Gregorio, Giuseppe, Boldrini, Luca, Tagliaferri, Luca, Indovina, Luca, Placidi, Lorenzo, Stimato, Gerardina, Spera, Francesco Raffaele, Scacciavillani, Roberto, Crea, Filippo, Valentini, Vincenzo, Pelargonio, Gemma, Cellini, Francesco (ORCID:0000-0002-2145-2300), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Crea, Filippo (ORCID:0000-0001-9404-8846), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco, Narducci, Maria Lucia, Pavone, Chiara, Bencardino, Gianluigi, Perna, Francesco, Pinnacchio, Gaetano, Chiesa, Silvia, Massaccesi, Mariangela, Gambacorta, Maria Antonietta, Manfrida, Stefania, Longo, Silvia, Mannocci, Alice, Di Gregorio, Giuseppe, Boldrini, Luca, Tagliaferri, Luca, Indovina, Luca, Placidi, Lorenzo, Stimato, Gerardina, Spera, Francesco Raffaele, Scacciavillani, Roberto, Crea, Filippo, Valentini, Vincenzo, Pelargonio, Gemma, Cellini, Francesco (ORCID:0000-0002-2145-2300), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Crea, Filippo (ORCID:0000-0001-9404-8846), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Introduction: Monomorphic ventricular tachycardia (VT) is a life-threatening condition often observed in patients with structural heart disease. Ventricular tachycardia ablation through radiation therapy (VT-ART) for sustained monomorphic ventricular tachycardia seems promising, effective, and safe. VT-ART delivers focused, high-dose radiation, usually in a single fraction of 25 Gy, allowing ablation of VT by inducing myocardial scars. The procedure is fully non-invasive; therefore, it can be easily performed in patients with contraindications to invasive ablation procedures. Definitive data are lacking, and no direct comparison with standard procedures is available.Discussion: The aim of this multicenter observational study is to evaluate the efficacy and safety of VT-ART, comparing the clinical outcome of patients undergone to VT-ART to patients not having received such a procedure. The two groups will not be collected by direct, prospective accrual to avoid randomization among the innovative and traditional arm: A retrospective selection through matched pair analysis will collect patients presenting features similar to the ones undergone VT-ART within the consortium (in each center independently). Our trial will enroll patients with optimized medical therapy in whom endocardial and/or epicardial radiofrequency ablation (RFA), the gold standard for VT ablation, is either unfeasible or fails to control VT recurrence. Our primary outcome is investigating the difference in overall cardiovascular survival among the group undergoing VT-ART and the one not exposed to the innovative procedure. The secondary outcome is evaluating the difference in ventricular event-free survival after the last procedure (i.e., last RFA vs. VT-ART) between the two groups. An additional secondary aim is to evaluate the reduction in the number of VT episodes comparing the 3 months before the procedure to the ones recorded at 6 months (from the 4th to 6th month) following VT-ART and RFA, resp
Published: 2023

5. Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience

Author: Chiloiro, Giuditta, Boldrini, Luca, Romano, Angela, Placidi, Lorenzo, Tran, Huong Elena, Nardini, Matteo, Massaccesi, Mariangela, Cellini, Francesco, Indovina, Luca, Gambacorta, Maria Antonietta, Cellini, Francesco (ORCID:0000-0002-2145-2300), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Chiloiro, Giuditta, Boldrini, Luca, Romano, Angela, Placidi, Lorenzo, Tran, Huong Elena, Nardini, Matteo, Massaccesi, Mariangela, Cellini, Francesco, Indovina, Luca, Gambacorta, Maria Antonietta, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737)
Abstract: PurposeStereotactic body radiotherapy is increasingly used for the treatment of oligometastatic disease. Magnetic resonance-guided stereotactic radiotherapy (MRgSBRT) offers the opportunity to perform dose escalation protocols while reducing the unnecessary irradiation of the surrounding organs at risk. The aim of this retrospective, monoinstitutional study is to evaluate the feasibility and clinical benefit (CB) of MRgSBRT in the setting of oligometastatic patients.Materials and methodsData from oligometastatic patients treated with MRgSBRT were collected. The primary objectives were to define the 12-month progression-free survival (PFS) and local progression-free survival (LPFS) and 24-month overall survival (OS) rate. The objective response rate (ORR) included complete response (CR) and partial response (PR). CB was defined as the achievement of ORR and stable disease (SD). Toxicities were also assessed according to the CTCAE version 5.0 scale.ResultsFrom February 2017 to March 2021, 59 consecutive patients with a total of 80 lesions were treated by MRgSBRT on a 0.35 T hybrid unit. CR and PR as well as SD were observed in 30 (37.5%), 7 (8.75%), and 17 (21.25%) lesions, respectively. Furthermore, CB was evaluated at a rate of 67.5% with an ORR of 46.25%.Median follow-up time was 14 months (range: 3-46 months). The 12-month LPFS and PFS rates were 70% and 23%, while 24-month OS rate was 93%. No acute toxicity was reported, whereas late pulmonary fibrosis G1 was observed in 9 patients (15.25%).ConclusionMRgSBRT was well tolerated by patients with reported low toxicity levels and a satisfying CB.
Published: 2023

6. Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis

Author: Mattiucci, Gian Carlo, Salvatore, Lisa, D'Aviero, Andrea, Bagalà, Cinzia, Bensi, Maria, Castronovo, Francesco Mosè, Cellini, Francesco, De Franco, Paola, Di Stefano, Brunella, Macchia, Gabriella, Masiello, Valeria, Menghi, Roberta, Quero, Giuseppe, Reina, Sara, Morganti, Alessio Giuseppe, Alfieri, Sergio, Tortora, Giampaolo, Valentini, Vincenzo, Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Cellini, Francesco (ORCID:0000-0002-2145-2300), Quero, Giuseppe (ORCID:0000-0002-0001-9479), Alfieri, Sergio (ORCID:0000-0002-0404-724X), Tortora, Giampaolo (ORCID:0000-0002-1378-4962), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Mattiucci, Gian Carlo, Salvatore, Lisa, D'Aviero, Andrea, Bagalà, Cinzia, Bensi, Maria, Castronovo, Francesco Mosè, Cellini, Francesco, De Franco, Paola, Di Stefano, Brunella, Macchia, Gabriella, Masiello, Valeria, Menghi, Roberta, Quero, Giuseppe, Reina, Sara, Morganti, Alessio Giuseppe, Alfieri, Sergio, Tortora, Giampaolo, Valentini, Vincenzo, Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Cellini, Francesco (ORCID:0000-0002-2145-2300), Quero, Giuseppe (ORCID:0000-0002-0001-9479), Alfieri, Sergio (ORCID:0000-0002-0404-724X), Tortora, Giampaolo (ORCID:0000-0002-1378-4962), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Introduction: Pancreatic cancer (PC) represents an unfavorable prognosis condition, even in patients with resectable disease. The aim of this series was to investigate the role of treatment intensification with adjuvant chemoradiation (CRT) in radically resected PC patients. Methods: Data from PC patients who underwent radical surgery, adjuvant chemotherapy (CT), and CRT throughout a 20-year period were retrospectively collected. Actuarial local control (LC) and the overall survival (OS) were the primary endpoints, with disease-free survival and metastasis-free survival (MFS) representing secondary endpoints. Results: The analysis included 108 PC patients treated with adjuvant CRT and CT from January 2000 to August 2019. Median age was 66 years (range: 40-83), and all patients underwent radical surgical resection with adjuvant CT (88, 81.5%) plus concomitant CRT (101, 93.5%) or radiotherapy alone (7, 6.5%). The median dose delivered to the tumor bed was 50.4 Gy (range: 45-50.6 Gy), while median dose to regional lymphatic drainage stations was 39.6 Gy (range 39.6-45 Gy). Concomitant CT was a gemcitabine-based regimen in the vast majority of patients (87, 80.6%). Median follow-up time was 21 months; the 2- and 5-year LC rates were 75.8% and 59.1%, respectively. Perineural invasion at pathological assessment was found significantly associated with LC (p = 0.028). Median OS was 40 months with 2- and 5-year OS rates of 73.9% and 41.6%, respectively. Conclusions: The outcomes of this series suggest to investigate the possible impact of adding adjuvant CRT to CT in PC patients. Timing and combination of modern CRT with new systemic therapies need to be further investigated to personalize therapy and optimize clinical advantages. (c) 2022 S. Karger AG, Basel
Published: 2022

7. Low Tesla magnetic resonance guided radiotherapy for locally advanced cervical cancer: first clinical experience

Author: Boldrini, Luca, Piras, Antonio, Chiloiro, Giuditta, Autorino, Rosa, Cellini, Francesco, Cusumano, Davide, Fionda, Bruno, D'Aviero, Andrea, Campitelli, Maura, Marazzi, Fabio, Balducci, Mario, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Cellini, Francesco (ORCID:0000-0002-2145-2300), Balducci, M (ORCID:0000-0003-0398-9726), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Boldrini, Luca, Piras, Antonio, Chiloiro, Giuditta, Autorino, Rosa, Cellini, Francesco, Cusumano, Davide, Fionda, Bruno, D'Aviero, Andrea, Campitelli, Maura, Marazzi, Fabio, Balducci, Mario, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Cellini, Francesco (ORCID:0000-0002-2145-2300), Balducci, M (ORCID:0000-0003-0398-9726), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737)
Abstract: N/A
Published: 2020

8. Evaluation of a simplified optimizer for MR-guided adaptive RT in case of pancreatic cancer

Author: Cusumano, Davide, Boldrini, Luca, Menna, Sebastiano, Teodoli, Stefania, Placidi, Elisa, Chiloiro, Giuditta, Placidi, Lorenzo, Greco, Francesca, Stimato, Gerardina, Cellini, Francesco, Valentini, Vincenzo, Azario, Luigi, De Spirito, Marco, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Azario, Luigi (ORCID:0000-0001-8575-8627), De Spirito, Marco (ORCID:0000-0003-4260-5107), Cusumano, Davide, Boldrini, Luca, Menna, Sebastiano, Teodoli, Stefania, Placidi, Elisa, Chiloiro, Giuditta, Placidi, Lorenzo, Greco, Francesca, Stimato, Gerardina, Cellini, Francesco, Valentini, Vincenzo, Azario, Luigi, De Spirito, Marco, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Azario, Luigi (ORCID:0000-0001-8575-8627), and De Spirito, Marco (ORCID:0000-0003-4260-5107)
Abstract: N/A
Published: 2019

9. Identification of the most significant magnetic resonance imaging (MRI) radiomic features in oncological patients with vertebral bone marrow metastatic disease: a feasibility study

Author: Filograna, Laura, Lenkowicz, Jacopo, Cellini, Francesco, Dinapoli, Nicola, Manfrida, Stefania, Magarelli, Nicola, Leone, Antonio, Colosimo, Cesare, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Magarelli, Nicola (ORCID:0000-0002-2521-086X), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Filograna, Laura, Lenkowicz, Jacopo, Cellini, Francesco, Dinapoli, Nicola, Manfrida, Stefania, Magarelli, Nicola, Leone, Antonio, Colosimo, Cesare, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Magarelli, Nicola (ORCID:0000-0002-2521-086X), Colosimo, Cesare (ORCID:0000-0003-3800-3648), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: n/a
Published: 2019

10. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach

Author: Boldrini, Luca, Cusumano, Davide, Chiloiro, Giuditta, Casà, Calogero, Masciocchi, Carlotta, Lenkowicz, Jacopo, Cellini, Francesco, Dinapoli, Nicola, Azario, Luigi, Teodoli, Stefania, Gambacorta, Maria Antonietta, De Spirito, Marco, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Azario, Luigi (ORCID:0000-0001-8575-8627), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), De Spirito, Marco (ORCID:0000-0003-4260-5107), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Boldrini, Luca, Cusumano, Davide, Chiloiro, Giuditta, Casà, Calogero, Masciocchi, Carlotta, Lenkowicz, Jacopo, Cellini, Francesco, Dinapoli, Nicola, Azario, Luigi, Teodoli, Stefania, Gambacorta, Maria Antonietta, De Spirito, Marco, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Azario, Luigi (ORCID:0000-0001-8575-8627), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), De Spirito, Marco (ORCID:0000-0003-4260-5107), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: N/A
Published: 2019

11. Multi-object tracking in MRI-guided radiotherapy using the tracking-learning-detection framework

Author: Dhont, Jennifer, Vandemeulebroucke, Jef, Cusumano, Davide, Boldrini, Luca, Cellini, Francesco, Valentini, Vincenzo, Verellen, Dirk, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Dhont, Jennifer, Vandemeulebroucke, Jef, Cusumano, Davide, Boldrini, Luca, Cellini, Francesco, Valentini, Vincenzo, Verellen, Dirk, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: N/A
Published: 2019

12. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival

Author: Morganti, Alessio Giuseppe, Cellini, Francesco, Buwenge, Milly, Arcelli, Alessandra, Alfieri, Sergio, Calvo, Felipe A, Casadei, Riccardo, Cilla, Savino, Deodato, Francesco, Di Gioia, Giancarmine, Di Marco, Mariacristina, Fuccio, Lorenzo, Bertini, Federica, Guido, Alessandra, Herman, Joseph M, Macchia, Gabriella, Maidment, Bert W, Miller, Robert C, Minni, Francesco, Passoni, Paolo, Valentini, Chiara, Perego, Alessia, Regine, William F, Reni, Michele, Falconi, Massimo, Valentini, Vincenzo, Mattiucci, Gian Carlo, Morganti, Alessio G, Cellini, Francesco (ORCID:0000-0002-2145-2300), Alfieri, Sergio (ORCID:0000-0002-0404-724X), Deodato, Francesco (ORCID:0000-0003-1276-5070), Re, Alessia, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Morganti, Alessio Giuseppe, Cellini, Francesco, Buwenge, Milly, Arcelli, Alessandra, Alfieri, Sergio, Calvo, Felipe A, Casadei, Riccardo, Cilla, Savino, Deodato, Francesco, Di Gioia, Giancarmine, Di Marco, Mariacristina, Fuccio, Lorenzo, Bertini, Federica, Guido, Alessandra, Herman, Joseph M, Macchia, Gabriella, Maidment, Bert W, Miller, Robert C, Minni, Francesco, Passoni, Paolo, Valentini, Chiara, Perego, Alessia, Regine, William F, Reni, Michele, Falconi, Massimo, Valentini, Vincenzo, Mattiucci, Gian Carlo, Morganti, Alessio G, Cellini, Francesco (ORCID:0000-0002-2145-2300), Alfieri, Sergio (ORCID:0000-0002-0404-724X), Deodato, Francesco (ORCID:0000-0003-1276-5070), Re, Alessia, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413)
Abstract: N/A
Published: 2019

13. Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study

Author: Bisello, Silvia, Buwenge, Milly, Palloni, Andrea, Autorino, Rosa, Cellini, Francesco, Macchia, Gabriella, Deodato, Francesco, Cilla, Savino, Brandi, Giovanni, Tagliaferri, Luca, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Mattiucci, Gian Carlo, Cammelli, Silvia, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Morganti, Alessio G, Mattiucci, Gian C (ORCID:0000-0001-6500-0413), Bisello, Silvia, Buwenge, Milly, Palloni, Andrea, Autorino, Rosa, Cellini, Francesco, Macchia, Gabriella, Deodato, Francesco, Cilla, Savino, Brandi, Giovanni, Tagliaferri, Luca, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Mattiucci, Gian Carlo, Cammelli, Silvia, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Morganti, Alessio G, and Mattiucci, Gian C (ORCID:0000-0001-6500-0413)
Abstract: N/A
Published: 2019

14. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer

Author: Valentini, Vincenzo, Gambacorta, Maria Antonietta, Cellini, Francesco, Aristei, Cynthia, Coco, Claudio, Barbaro, Brunella, Alfieri, Sergio, D'Ugo, Domenico, Persiani, Roberto, Deodato, Francesco, Crucitti, Antonio, Lupattelli, Marco, Mantello, Giovanna, Navarria, Federico, Belluco, Claudio, Buonadonna, Angela, Boso, Caterina, Lonardi, Sara, Caravatta, Luciana, Barba, Maria Cristina, Vecchio, Fabio Maria, Maranzano, Ernesto, Genovesi, Domenico, Doglietto, Giovanni Battista, Morganti, Alessio Giuseppe, La Torre, Giuseppe, Pucciarelli, Salvatore, De Paoli, Antonino, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), Coco, Claudio (ORCID:0000-0002-4713-7093), Barbaro, Brunella (ORCID:0000-0002-9638-543X), Alfieri, Sergio (ORCID:0000-0002-0404-724X), D'Ugo, Domenico (ORCID:0000-0001-6657-6318), Persiani, Roberto (ORCID:0000-0002-1537-5097), Deodato, Francesco (ORCID:0000-0003-1276-5070), Crucitti, Antonio (ORCID:0000-0003-3496-4185), Vecchio, Fabio Maria (ORCID:0000-0002-9197-2264), Valentini, Vincenzo, Gambacorta, Maria Antonietta, Cellini, Francesco, Aristei, Cynthia, Coco, Claudio, Barbaro, Brunella, Alfieri, Sergio, D'Ugo, Domenico, Persiani, Roberto, Deodato, Francesco, Crucitti, Antonio, Lupattelli, Marco, Mantello, Giovanna, Navarria, Federico, Belluco, Claudio, Buonadonna, Angela, Boso, Caterina, Lonardi, Sara, Caravatta, Luciana, Barba, Maria Cristina, Vecchio, Fabio Maria, Maranzano, Ernesto, Genovesi, Domenico, Doglietto, Giovanni Battista, Morganti, Alessio Giuseppe, La Torre, Giuseppe, Pucciarelli, Salvatore, De Paoli, Antonino, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), Coco, Claudio (ORCID:0000-0002-4713-7093), Barbaro, Brunella (ORCID:0000-0002-9638-543X), Alfieri, Sergio (ORCID:0000-0002-0404-724X), D'Ugo, Domenico (ORCID:0000-0001-6657-6318), Persiani, Roberto (ORCID:0000-0002-1537-5097), Deodato, Francesco (ORCID:0000-0003-1276-5070), Crucitti, Antonio (ORCID:0000-0003-3496-4185), and Vecchio, Fabio Maria (ORCID:0000-0002-9197-2264)
Abstract: N/A
Published: 2019

15. A new frontier of image guidance: Organs at risk avoidance with MRI-guided respiratory-gated intensity modulated radiotherapy: Technical note and report of a case

Author: Massaccesi, Mariangela, Cusumano, Davide, Boldrini, Luca, Dinapoli, Nicola, Fionda, Bruno, Teodoli, Stefania, Azario, Luigi, Mattiucci, Gian Carlo, Balducci, Mario, Cellini, Francesco, Valentini, Vincenzo, Azario, Luigi (ORCID:0000-0001-8575-8627), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Balducci, Mario (ORCID:0000-0003-0398-9726), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Massaccesi, Mariangela, Cusumano, Davide, Boldrini, Luca, Dinapoli, Nicola, Fionda, Bruno, Teodoli, Stefania, Azario, Luigi, Mattiucci, Gian Carlo, Balducci, Mario, Cellini, Francesco, Valentini, Vincenzo, Azario, Luigi (ORCID:0000-0001-8575-8627), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Balducci, Mario (ORCID:0000-0003-0398-9726), Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: N/A
Published: 2019

16. MR-guided radiotherapy in rectal cancer: First clinical experience of an innovative technology

Author: Chiloiro, Giuditta, Boldrini, Luca, Meldolesi, Elisa, Perego, Alessia, Cellini, Francesco, Cusumano, Davide, Corvari, Mantini, Giovanna, Balducci, Mario, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Re, Alessia, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Balducci, Mario (ORCID:0000-0003-0398-9726), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Chiloiro, Giuditta, Boldrini, Luca, Meldolesi, Elisa, Perego, Alessia, Cellini, Francesco, Cusumano, Davide, Corvari, Mantini, Giovanna, Balducci, Mario, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Re, Alessia, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Balducci, Mario (ORCID:0000-0003-0398-9726), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737)
Abstract: N/A
Published: 2019

17. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls

Author: Boldrini, Luca, Cusumano, Davide, Cellini, Francesco, Azario, Luigi, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Azario, Luigi (ORCID:0000-0001-8575-8627), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Boldrini, Luca, Cusumano, Davide, Cellini, Francesco, Azario, Luigi, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Azario, Luigi (ORCID:0000-0001-8575-8627), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: N/A
Published: 2019

18. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers

Author: Caravatta, Luciana, Cellini, Francesco, Simoni, Nicola, Rosa, Consuelo, Niespolo, Rita Marina, Lupattelli, Marco, Picardi, Vincenzo, Macchia, Gabriella, Sainato, Aldo, Mantello, Giovanna, Dionisi, Francesco, Rosetto, Maria Elena, Fusco, Vincenzo, Navarria, Federico, De Paoli, Antonino, Guido, Alessandra, Vecchi, Claudio, Basilico, Raffaella, Cianci, Roberta, Delli Pizzi, Andrea, Di Nicola, Marta, Mattiucci, Gian Carlo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Genovesi, Domenico, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Caravatta, Luciana, Cellini, Francesco, Simoni, Nicola, Rosa, Consuelo, Niespolo, Rita Marina, Lupattelli, Marco, Picardi, Vincenzo, Macchia, Gabriella, Sainato, Aldo, Mantello, Giovanna, Dionisi, Francesco, Rosetto, Maria Elena, Fusco, Vincenzo, Navarria, Federico, De Paoli, Antonino, Guido, Alessandra, Vecchi, Claudio, Basilico, Raffaella, Cianci, Roberta, Delli Pizzi, Andrea, Di Nicola, Marta, Mattiucci, Gian Carlo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Genovesi, Domenico, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: n/a
Published: 2019

19. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis

Author: Mattiucci, Gian Carlo, Morganti, Alessio Giuseppe, Cellini, Francesco, Buwenge, Milly, Casadei, Riccardo, Farioli, Andrea, Alfieri, Sergio, Arcelli, Alessandra, Bertini, Federica, Calvo, Felipe A., Cammelli, Silvia, Fuccio, Lorenzo, Giaccherini, Lucia, Guido, Alessandra, Herman, Joseph M., Macchia, Gabriella, Maidment, Bert W., Miller, Robert C., Minni, Francesco, Regine, William F., Reni, Michele, Partelli, Stefano, Falconi, Massimo, Valentini, Vincenzo, Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Morganti, Alessio G., Cellini, Francesco (ORCID:0000-0002-2145-2300), Alfieri, Sergio (ORCID:0000-0002-0404-724X), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Mattiucci, Gian Carlo, Morganti, Alessio Giuseppe, Cellini, Francesco, Buwenge, Milly, Casadei, Riccardo, Farioli, Andrea, Alfieri, Sergio, Arcelli, Alessandra, Bertini, Federica, Calvo, Felipe A., Cammelli, Silvia, Fuccio, Lorenzo, Giaccherini, Lucia, Guido, Alessandra, Herman, Joseph M., Macchia, Gabriella, Maidment, Bert W., Miller, Robert C., Minni, Francesco, Regine, William F., Reni, Michele, Partelli, Stefano, Falconi, Massimo, Valentini, Vincenzo, Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Morganti, Alessio G., Cellini, Francesco (ORCID:0000-0002-2145-2300), Alfieri, Sergio (ORCID:0000-0002-0404-724X), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: BACKGROUND: Presurgical carbohydrate antigen 19-9 (CA19-9) level predicts overall survival (OS) in resected pancreatic adenocarcinoma (PaC). The aim of this pooled analysis was to evaluate if presurgical CA19-9 level can also predict local control (LC) and distant metastasis-free survival (DMFS). METHODS: Seven hundred patients with PaC from eight institutions who underwent surgical resection ± adjuvant treatment between 2000 and 2014 were analyzed. Patients were divided based on four presurgical CA19-9 level cutoffs (5, 37, 100, 353 U/ml). Weibull regression model to identify independent predictors of OS on 404 patients with complete information was fitted. RESULTS: Median follow-up was 17 months (range: 2-225 months). Univariate analysis showed a better prognosis in pT1-2, pN0, diameter <30 mm, or grade 1 tumors and in patients undergoing R0 resection, distal pancreatectomy, or adjuvant chemotherapy and with lower CA19-9 levels. Five-year OS, LC, and DMFS were as follows: CA19-9 <5.0: 5.7%, 47.2%, 17.0%; CA19-9 5.1-37.0: 37.9%, 63.3%, 46.0%; CA19-9 37.1-100.0: 27.1%, 59.4%, 39.0%; CA19-9 100.1-353.0: 17.4%, 43.4%, 26.7%; CA19-9 >353.1: 10.9%, 50.2%, and 23.4%, respectively. At multivariate analysis, CA19-9 >100 and <353 level (P=.002), CA19-9 ≥353.1 (P<.001) level, G3 tumor (P=.002), and tumor diameter >30 mm (P<.001) correlated with worse OS. Patients treated with postoperative chemoradiation doses >50.0 Gy showed improved OS (P<.001). CONCLUSION: Presurgical CA19-9 predicts both OS and pattern of failure. Therefore, CA19-9 should be included in predictive models in order to customize treatments based on prognostic factors. Moreover, future studies should stratify patients according to presurgical CA19-9 level.
Published: 2019

20. Hybrid Tri-Co-60 MRI radiotherapy for locally advanced rectal cancer: An in silico evaluation

Author: Boldrini, Luca, Placidi, Elisa, Dinapoli, Nicola, Azario, Luigi, Cellini, Francesco, Massaccesi, Mariangela, Chiesa, Silvia, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Piccari, Danila, Teodoli, Stefania, De Spirito, Marco, Valentini, Vincenzo, Azario, Luigi (ORCID:0000-0001-8575-8627), Cellini, Francesco (ORCID:0000-0002-2145-2300), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), De Spirito, Marco (ORCID:0000-0003-4260-5107), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Boldrini, Luca, Placidi, Elisa, Dinapoli, Nicola, Azario, Luigi, Cellini, Francesco, Massaccesi, Mariangela, Chiesa, Silvia, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Piccari, Danila, Teodoli, Stefania, De Spirito, Marco, Valentini, Vincenzo, Azario, Luigi (ORCID:0000-0001-8575-8627), Cellini, Francesco (ORCID:0000-0002-2145-2300), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), De Spirito, Marco (ORCID:0000-0003-4260-5107), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: n/a
Published: 2018

21. Use of Indirect Target Gating in Magnetic Resonance-guided Liver Stereotactic Body Radiotherapy: Case Report of an Oligometastatic Patient

Author: Boldrini, Luca, Cellini, Francesco, Manfrida, Stefania, Chiloiro, Giuditta, Teodoli, Stefania, Cusumano, Davide, Fionda, Bruno, Mattiucci, Gian Carlo, De Gaetano, Anna Maria, Azario, Luigi, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), De Gaetano, Anna Maria (ORCID:0000-0002-7493-9462), Azario, Luigi (ORCID:0000-0001-8575-8627), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Boldrini, Luca, Cellini, Francesco, Manfrida, Stefania, Chiloiro, Giuditta, Teodoli, Stefania, Cusumano, Davide, Fionda, Bruno, Mattiucci, Gian Carlo, De Gaetano, Anna Maria, Azario, Luigi, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), De Gaetano, Anna Maria (ORCID:0000-0002-7493-9462), Azario, Luigi (ORCID:0000-0001-8575-8627), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: The case of a 73-year-old woman affected by anal canal cancer with concomitant liver metastases is presented here. The patient was addressed to stereotactic body radiotherapy (SBRT) on two hepatic secondary lesions after the first radiochemotherapy treatment of the primary tumor. A Tri-60-Co magnetic resonance hybrid radiotherapy unit was used for SBRT treatment delivery. Both liver lesions were not clearly visible on the setup magnetic resonance imaging (MRI) due to their limited dimensions (maximum diameter 13 mm); however, the presence of two cysts adjacent to the metastases allowed the use of an indirect target gating approach. Treatment was delivered in deep inspiration breath-hold conditions using the visual feedback technique for breathing control optimization. Post radiotherapy imaging assessed the complete response.
Published: 2018

22. Short course accelerated radiation therapy (SHARON) in palliative treatment of advanced solid cancer in older patients: A pooled analysis

Author: Farina, Eleonora, Capuccini, Jenny, Macchia, Gabriella, Caravatta, Luciana, Nguyen, Nam P., Cammelli, Silvia, Zanirato Rambaldi, Giuseppe, Cilla, Savino, Wondemagegnhu, Tigeneh, Uddin, A. F. M. Kamal, Sumon, Mostafà Aziz, Genovesi, Domenico, Buwenge, Milly, Cellini, Francesco, Valentini, Vincenzo, Deodato, Francesco, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Deodato, Francesco (ORCID:0000-0003-1276-5070), Morganti, Alessio G., Farina, Eleonora, Capuccini, Jenny, Macchia, Gabriella, Caravatta, Luciana, Nguyen, Nam P., Cammelli, Silvia, Zanirato Rambaldi, Giuseppe, Cilla, Savino, Wondemagegnhu, Tigeneh, Uddin, A. F. M. Kamal, Sumon, Mostafà Aziz, Genovesi, Domenico, Buwenge, Milly, Cellini, Francesco, Valentini, Vincenzo, Deodato, Francesco, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Deodato, Francesco (ORCID:0000-0003-1276-5070), and Morganti, Alessio G.
Abstract: Objectives: To evaluate the efficacy and safety of a conformal Short Course Accelerated Radiation therapy (SHARON) for symptomatic palliation of locally advanced or metastatic cancers in older patients. Materials and Methods: This is a pooled analysis on patients aged â¥. 80 years selected between subjects enrolled in 3 phase I-II studies on a short course palliative treatment of advanced or metastatic cancer. The primary endpoint was to evaluate the symptoms response rate produced by accelerated radiotherapy delivered in 4 total fractions in twice a day. Total dose ranged between 14 Gy and 20 Gy while dose/fraction between 3.5 and 5 Gy. Results: A total of 48 patients were included in this analysis. Twenty-six patients (54.2%) had advanced primary or metastatic head and neck tumors, 11 (22.9%) locally advanced or metastatic thoracic cancers, 11 (22.9%) complicated bone metastases. The majority of patients presented pain (60.4%). With a median follow-up time of 5.5 months, no G4 acute and late toxicities were recorded. The overall palliative response rate was 91.7% with a median duration of palliation of 4 months. Conclusion: Short course accelerated radiotherapy in locally advanced or metastatic cancers is effective in terms of symptom relief and well tolerated even in older patients.
Published: 2018

23. Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies

Author: Marinelli, Ilaria, Guido, Alessandra, Fuccio, Lorenzo, Farioli, Andrea, Panni, Valeria, Giaccherini, Lucia, Arcelli, Alessandra, Ercolani, Giorgio, Brandi, Giovanni, Cammelli, Silvia, Galuppi, Andrea, Macchia, Gabriella, Frakulli, Rezarta, Mattiucci, Gian Carlo, Cellini, Francesco, Buwenge, Milly, Renzulli, Matteo, Deodato, Francesco, Cilla, Savino, Valentini, Vincenzo, Tombolini, Vincenzo, Golfieri, Rita, Morganti, Alessio Giuseppe, Mattiucci, Gian C (ORCID:0000-0001-6500-0413), Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Morganti, Alessio G, Marinelli, Ilaria, Guido, Alessandra, Fuccio, Lorenzo, Farioli, Andrea, Panni, Valeria, Giaccherini, Lucia, Arcelli, Alessandra, Ercolani, Giorgio, Brandi, Giovanni, Cammelli, Silvia, Galuppi, Andrea, Macchia, Gabriella, Frakulli, Rezarta, Mattiucci, Gian Carlo, Cellini, Francesco, Buwenge, Milly, Renzulli, Matteo, Deodato, Francesco, Cilla, Savino, Valentini, Vincenzo, Tombolini, Vincenzo, Golfieri, Rita, Morganti, Alessio Giuseppe, Mattiucci, Gian C (ORCID:0000-0001-6500-0413), Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Morganti, Alessio G
Abstract: Background/Aim: Radiotherapy is a treatment option for both adjuvant and neo-adjuvant settings for biliary tract cancer. Guidelines on the delineation of the target volume of lymph nodes are lacking; only generic indications are available, without specific recommendations for different primary tumour locations (e.g. intrahepatic, extrahepatic biliary tract or gallbladder cancer). The aim of this study was to systematically review available literature to provide recommendations on lymph node target volume delineation in patients with unresectable biliary tumour. Materials and Methods: A systematic search of electronic databases was performed up to July 2016. The primary outcome measure was the rate of lymph node involvement according to the location of primary biliary tumour. Sites with = 5% of nodal metastases were considered in the clinical target volume for radiotherapy planning. Results: Twelve studies (1075 patients) were included. The most frequent site of lymph node metastasis in intrahepatic biliary tree carcinoma was retroportal (61.1%, 95% confidence interval (CI)= 50.7-706%). Other frequently involved lymph nodes were along the hepatoduodenal ligament [ frequency=38.7%, 95% CI=31.0-47.0%], those along the common hepatic artery (17.0%, 95% CI=8.2-31.9%) and the hilar nodes (16.9%, 95% CI=13.2-21.4%). In extrahepatic biliary tree cancer, the most frequently involved lymph nodes were the pericholedochal (42.7%, 95% CI=33.8-52.1%) and those along the hepatoduodenal ligament (40.3%, 95% CI=32.4-48.8%). Other commonly involved nodal regions included retroportal lymph nodes (30.9%, 95% CI=23.0-40.1%), pancreaticoduodenal anterior and posterior nodes (30.1%, 95% CI=12.2-57.1%), those along the common hepatic artery (19.7%, 95% CI=11.8-31.0%) and para_aortic nodes (15.2%, 95% CI=8.0-27.0%). The most common site of metastases in gallbladder cancer were the pericholedochal nodes (25.2%, 95% CI=18.6-33.2%), those along the cystic duct (23%, 95% CI=16.6-30.8%), and ret
Published: 2017

24. Multimodal treatment of resectable pancreatic ductal adenocarcinoma

Author: Silvestris, Nicola, Brunetti, Oronzo, Vasile, Enrico, Cellini, Francesco, Cataldo, Ivana, Pusceddu, Valeria, Cattaneo, Monica, Partelli, Stefano, Scartozzi, Mario, Aprile, Giuseppe, Casadei Gardini, Andrea, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Scarpa, Aldo, Falconi, Massimo, Calabrese, Angela, Lorusso, Vito, Reni, Michele, Cascinu, Stefano, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Silvestris, Nicola, Brunetti, Oronzo, Vasile, Enrico, Cellini, Francesco, Cataldo, Ivana, Pusceddu, Valeria, Cattaneo, Monica, Partelli, Stefano, Scartozzi, Mario, Aprile, Giuseppe, Casadei Gardini, Andrea, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Scarpa, Aldo, Falconi, Massimo, Calabrese, Angela, Lorusso, Vito, Reni, Michele, Cascinu, Stefano, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.
Published: 2017

25. Role of the modern radiotherapy in the postoperative setting for esophageal cancer

Author: Mattiucci, Gian Carlo, Cellini, Francesco, Mattiucci, Gian-Carlo (ORCID:0000-0001-6500-0413), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo, Cellini, Francesco, Mattiucci, Gian-Carlo (ORCID:0000-0001-6500-0413), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Abstract: N/A
Published: 2017

26. Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study

Author: Picardi, Vincenzo, Macchia, Gabriella, Guido, Alessandra, Giaccherini, Lucia, Deodato, Francesco, Farioli, Andrea, Cilla, Savino, Compagnone, Gaetano, Ardizzoni, Andrea, Cuicchi, Dajana, Gambacorta, Maria Antonietta, Cellini, Francesco, Frezza, Giovanni, Poggioli, Gilberto, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Picardi, Vincenzo, Macchia, Gabriella, Guido, Alessandra, Giaccherini, Lucia, Deodato, Francesco, Farioli, Andrea, Cilla, Savino, Compagnone, Gaetano, Ardizzoni, Andrea, Cuicchi, Dajana, Gambacorta, Maria Antonietta, Cellini, Francesco, Frezza, Giovanni, Poggioli, Gilberto, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Purpose: The aim of this study was to investigate the efficacy and toxicity of volumetric modulated arc therapy (VMAT)-simultaneous integrated boost (SIB) in preoperative combined treatment of locally advanced rectal cancer. Methods: Radiation therapy was performed using the VMAT-SIB technique. The dose to mesorectum and pelvic lymph nodes was 45 Gy (1.8 Gy/fraction). A concomitant boost was delivered on GTV + 2-cm margin with a total dose of 57.5 Gy (2.3 Gy/fraction). The following concomitant chemotherapy was administered: capecitabine (825 mg/m2 twice daily, 5 days per week) and oxaliplatin (130 mg/m2 on days 1, 17, and 35). Efficacy was evaluated in terms of complete pathological response (pCR). Acute toxicities were evaluated according to Common Terminology Criteria for Adverse Events version 3.0 criteria. Results: A total of 18 patients (7 women; median age 62 years; clinical stage: 4 local recurrences, 6 cT4, 5 cT3, 3 cT2, 2 cN0, 7 cN1, 9 cN2) were enrolled. Sixteen patients underwent surgical resection (9 low anterior resection, 6 abdominal perineal amputations; 1 transanal excision) and 2 patients did not undergo surgery for early metastatic progression or death from acute pulmonary edema. R0 resection was achieved in all patients who underwent surgery. Overall, 4 patients had a pCR and 7 patients only a microscopic residual of disease (pT0-Tmic: 11/18 = 61.1%; 95% CI, 36.2-86.1). Acute grade ≥ 3 toxicity was as follows: 1 case of leukopenia, 1 skin toxicity, 1 genitourinary toxicity, and 5 gastrointestinal toxicities, with an overall incidence of 8 (44.4%) of 18 patients. One-, 3-, and 5-year cumulative local control was 100%, 68.6%, and 68.6%, respectively. One-, 3-, and 5-year cumulative disease-free survival was 88.9%, 66.7%, and 66.7%, respectively. One-, 3-, and 5-year cumulative overall survival was 85%, 63.8%, and 63.8%, respectively. Conclusion: The regimen used in this study showed excellent results in terms of pathologic responses. However, despi
Published: 2017

27. Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study

Author: Buwenge, Milly, Cilla, Savino, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Deodato, Francesco, Cammelli, Silvia, Cellini, Francesco, Mattiucci, Gian Carlo, Valentini, Vincenzo, Stock, Marku, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Buwenge, Milly, Cilla, Savino, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Deodato, Francesco, Cammelli, Silvia, Cellini, Francesco, Mattiucci, Gian Carlo, Valentini, Vincenzo, Stock, Marku, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Aim Aim of this study was to perform a planning feasibility analysis of a 3-level dose prescription using an IMRT-SIB technique. Background Radiation therapy of locally advanced pancreatic cancer should administer a minimum dose to the duodenum and a very high dose to the vascular infiltration areas to improve the possibility of a radical resection. Materials and methods Fifteen patients with pancreatic head adenocarcinoma and vascular involvement were included. The duodenal PTV (PTVd) was defined as the GTV overlapping the duodenal PRV. Vascular CTV (CTVv) was defined as the surface of contact or infiltration between the tumor and vessel plus a 5 mm margin. Vascular PTV (PTVv) was considered as the CTVv plus an anisotropic margin. The tumor PTV (PTVt) was defined as the GTV plus a margin including the PTVv and excluding the PTVd. The following doses were prescribed: 30 Gy (6 Gy/fraction) to PTVd, 37.5 Gy (7.5 Gy/fraction) to PTVt, and 45 Gy (9 Gy/fraction) to PTVv, respectively. Treatment was planned with an IMRT technique. Results The primary end-point (PTVv Dmean > 90%) was achieved in all patients. PTVv D98% > 90% was achieved in 6 patients (40%). OARs constraints were achieved in all patients. Conclusions Although the PTVv D95% > 95% objective was achieved only in 40% of patients, the study showed that in 100% of patients it was possible to administer a strongly differentiated mean/median dose. Prospective trials based on clinical application of this strategy seem to be justified in selected patients without overlap between PTVd and PTVv.
Published: 2016

28. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

Author: Silvestris, Nicola, Longo, Vito, Cellini, Francesco, Reni, Michele, Bittoni, Alessandro, Cataldo, Ivana, Partelli, Stefano, Falconi, Massimo, Scarpa, Aldo, Brunetti, Oronzo, Lorusso, Vito, Santini, Daniele, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Cascinu, Stefano, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Silvestris, Nicola, Longo, Vito, Cellini, Francesco, Reni, Michele, Bittoni, Alessandro, Cataldo, Ivana, Partelli, Stefano, Falconi, Massimo, Scarpa, Aldo, Brunetti, Oronzo, Lorusso, Vito, Santini, Daniele, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Cascinu, Stefano, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.
Published: 2016

29. Palliative short-course radiation therapy in rectal cancer: A phase 2 study

Author: Picardi, Vincenzo, Deodato, Francesco, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Frazzoni, Leonardo, Farioli, Andrea, Cuicchi, Dajana, Cilla, Savino, Cellini, Francesco, Uddin, A. F. M. Kamal, Gambacorta, Maria Antonietta, Buwenge, Milly, Ardizzoni, Andrea, Poggioli, Gilberto, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Cellini, Francesco (ORCID:0000-0002-2145-2300), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Picardi, Vincenzo, Deodato, Francesco, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Frazzoni, Leonardo, Farioli, Andrea, Cuicchi, Dajana, Cilla, Savino, Cellini, Francesco, Uddin, A. F. M. Kamal, Gambacorta, Maria Antonietta, Buwenge, Milly, Ardizzoni, Andrea, Poggioli, Gilberto, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Cellini, Francesco (ORCID:0000-0002-2145-2300), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Purpose The management of patients with symptomatic rectal cancer not amenable to curative treatment may be challenging. The aim of this phase 2 study was to evaluate the efficacy of short-course radiation therapy in patients with obstructing rectal cancer. Methods and Materials Patients who were not candidates for surgical resection because of synchronous metastases, age, and/or comorbidities were considered eligible. The sample size was calculated based on the 2-stage design of Simon. Short-course radiation therapy was delivered with an isocentric 4-field box technique (total, 25 Gy; 5 fractions in 5 days). Chemotherapy was suspended during radiation treatment. Clinical outcome measures were symptomatic response rate, toxicity, colostomy-free survival, and overall survival. Results From October 2003 to November 2012, 18 patients (median age, 77.5 years) were enrolled. The median follow-up was 11.5 months (range, 3-36 months). Four weeks after treatment, a complete response (ie, complete symptom resolution) was observed in 38.9% of patients and a partial response in 50.0% cases, whereas 11.1% had no response. The rates of reduction or resolution of pain and bleeding were 87.5% and 100%, respectively. The 1-, 2-, and 3-year colostomy-free survival rates were 100%, 71.4%, and 47.6%, respectively (median, 30 months). The 1-, 2-, and 3-year cumulative overall survival rates were 85.2%, 53%, and 39.8%, respectively (median, 25 months). No patients stopped treatment because of gastrointestinal or genitourinary toxicities: 38.9% of patients had grade 1 to 2 toxicity, and 16.7% had grade 3 toxicity. Only 1 patient had hematologic grade 2 toxicity, and 2 patients had grade 2 skin toxicity. Conclusions Short-course radiation therapy may represent a safe and effective alternative treatment option in patients with obstructing rectal cancer not eligible for curative treatment, allowing colostomy to be avoided in a substantial proportion of patients.
Published: 2016

30. Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Author: Morganti, Alessio Giuseppe, Cellini, Francesco, Mignogna, Samantha, Padula, Gilbert Da, Caravatta, Luciana, Deodato, Francesco, Picardi, Vincenzo, Macchia, Gabriella, Cilla, Savino, Buwenge, Milly, Lullo, Liberato DI, Gambacorta, Maria Antonietta, Balducci, Mario, Mattiucci, Gian Carlo, Autorino, Rosa, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Balducci, Mario (ORCID:0000-0003-0398-9726), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Morganti, Alessio Giuseppe, Cellini, Francesco, Mignogna, Samantha, Padula, Gilbert Da, Caravatta, Luciana, Deodato, Francesco, Picardi, Vincenzo, Macchia, Gabriella, Cilla, Savino, Buwenge, Milly, Lullo, Liberato DI, Gambacorta, Maria Antonietta, Balducci, Mario, Mattiucci, Gian Carlo, Autorino, Rosa, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Balducci, Mario (ORCID:0000-0003-0398-9726), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.
Published: 2016

31. Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Author: Picardi, Vincenzo, Deodato, Francesco, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Gambacorta, Maria Antonietta, Arcelli, Alessandra, Farioli, Andrea, Cellini, Francesco, Cuicchi, Dajana, DI Fabio, Francesca, Poggioli, Gilberto, Ardizzoni, Andrea, Frezza, Giovanni, Cilla, Savino, Caravatta, Luciana, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Picardi, Vincenzo, Deodato, Francesco, Guido, Alessandra, Giaccherini, Lucia, Macchia, Gabriella, Gambacorta, Maria Antonietta, Arcelli, Alessandra, Farioli, Andrea, Cellini, Francesco, Cuicchi, Dajana, DI Fabio, Francesca, Poggioli, Gilberto, Ardizzoni, Andrea, Frezza, Giovanni, Cilla, Savino, Caravatta, Luciana, Valentini, Vincenzo, Fuccio, Lorenzo, Morganti, Alessio Giuseppe, Deodato, Francesco (ORCID:0000-0003-1276-5070), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: AIM: The aim of this study was to evaluate the pathological response of locally advanced rectal cancer after preoperative concurrent two-drug chemotherapy and intensified radiation therapy (RT) with concomitant boost. PATIENTS AND METHODS: Patients with T4 tumor or local recurrence were included. A trial based on two-stage Simon's design was planned. RT was performed with 3D-conformal technique. The dose to the mesorectum and pelvic lymph nodes was 45 Gy (1.8 Gy/fraction). A concomitant boost was delivered to Gross Tumor Volume (GTV) 2 cm margin to a total dose of 55 Gy (2.2 Gy/fraction). The following concurrent chemotherapy was administered: Raltitrexed (3 mg/m(2)) and oxaliplatin (130 mg/m(2)) on days 1, 17, and 35 of RT. Pathological response was evaluated according to the Mandard classification. Toxicities were scored according to the Common Terminology Criteria for Adverse Events v3.0 scale. RESULTS: Eighteen patients (median age=64.5 years) were enrolled. The median follow-up was 22 months (range=2-36 months). After chemoradiation treatment, 16 patients underwent surgical resection (seven anterior resections and nine abdominal-perineal amputation); two patients did not undergo surgery due to early metastatic progression or refusal. R0 resection was achieved in all patients who underwent surgery. Five patients had pathological complete response [27.7%; 95% confidence interval (CI)=9.7-53.5%] and two patients showed only microscopic residual disease (11.1%; 95% CI=0.1-34.7%). Mandard grades 1 and 2 were detected in seven patients (38.9%; 95% CI=17.3-64.3%). Acute grade 3 or more toxicity was found in eight patients (44.4%; 95% CI=21.5-69.2%): one leucopenia-neutropenia, one liver, one skin and five cases of gastrointestinal toxicities. No patient had local tumor recurrence. One-, 2- and 3-year cumulative disease-free survival were 93.8%. One-, 2- and 3-year cumulative overall survival were 92.3%. CONCLUSION: Concurrent chemoradiation with concomitant boost in p
Published: 2016

32. Underuse of brachytherapy for the treatment of dysphagia owing to esophageal cancer. An Italian survey

Author: Fuccio, Lorenzo, Guido, Alessandra, Hassan, Cesare, Frazzoni, Leonardo, Arcelli, Alessandra, Farioli, Andrea, Giaccherini, Lucia, Galuppi, Andrea, Mandolesi, Daniele, Cellini, Francesco, Mantello, Giovanna, Macchia, Gabriella, de Bortoli, Nicola, Repici, Alessandro, Valentini, Vincenzo, Bazzoli, Franco, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Fuccio, Lorenzo, Guido, Alessandra, Hassan, Cesare, Frazzoni, Leonardo, Arcelli, Alessandra, Farioli, Andrea, Giaccherini, Lucia, Galuppi, Andrea, Mandolesi, Daniele, Cellini, Francesco, Mantello, Giovanna, Macchia, Gabriella, de Bortoli, Nicola, Repici, Alessandro, Valentini, Vincenzo, Bazzoli, Franco, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Background International guidelines strongly recommend brachytherapy as valid alternative or in addition to stenting in patients with dysphagia owing to esophageal cancer. However, for not well understood reasons, brachytherapy is definitively underused for the palliative treatment of malignant dysphagia. Aim of the current survey was to investigate the use of brachytherapy for the treatment of malignant dysphagia in Italy. Methods A structured questionnaire was submitted to the 1510 members of the Italian Association of Radiation Oncologists (AIRO). These members refer to 177 centres of radiotherapy across Italy and in 68 (38.4%) of them brachytherapy is routinely performed. Results Of the 1510 invited members, 178 completed the survey (11.7%). The answers provided by the 178 participants allowed to get information on 40 out of 68 brachytherapy centres (58.8%). Seven out of 40 (17.5%) centres perform brachytherapy of the oesophagus, in 3 out of 40 (7.5%) centres brachytherapy represents the first line of treatment. The main reason why brachytherapy is not routinely performed is the lack of experience. Conclusion Despite the strong recommendations of the international guidelines and the wide diffusion of brachytherapy centres across Italy, only very few of them routinely considered brachytherapy for the treatment of dysphagia due to esophageal cancer.
Published: 2016

33. Robotic radiosurgery in pancreatic cancer: A systematic review

Author: Buwenge, M, Cellini, Francesco, Silvestris, N, Cilla, Savino, Deodato, Francesco, Macchia, Gabriella, Mattiucci, Gian Carlo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Buwenge, M, Cellini, Francesco, Silvestris, N, Cilla, Savino, Deodato, Francesco, Macchia, Gabriella, Mattiucci, Gian Carlo, Valentini, Vincenzo, Morganti, Alessio Giuseppe, Cellini, Francesco (ORCID:0000-0002-2145-2300), Deodato, Francesco (ORCID:0000-0003-1276-5070), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: To present a systematic review of techniques and clinical results.
Published: 2015

34. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach

Author: Cellini, Francesco, Morganti, Alessio Giuseppe, Di Matteo, Fm, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco, Morganti, Alessio Giuseppe, Di Matteo, Fm, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Gastroesophageal cancers (such as esophageal, gastric and gastroesophageal-junction -GEJ- lesions) are worldwide a leading cause of death being relatively rare but highly aggressive. In the past years, a clear shift in the location of upper gastrointestinal tract tumors has been recorded, both affecting the scientific research and the modern clinical practice. The integration of pre- or peri-operative multimodal approaches, as radiotherapy and chemotherapy (often combined), seems promising to further improve clinical outcome for such presentations. In the past, the definition of GEJ led to controversies and confusion: GEJ tumors have been managed either grouped to gastric or esophageal lesions, following slightly different surgical, radiotherapeutic and systemic approaches. Recently, the American Joint Committee on Cancer (AJCC) changed the staging and classification system of GEJ to harmonize some staging issues for esophageal and gastric cancer. This review discusses the most relevant historical and recent evidences of neoadjuvant treatment involving Radiotherapy for GEJ tumors, and describes the efficacy of such treatment in the frame of multimodal integrated therapies, from the new point of view of the recent classification of such tumors.
Published: 2014

35. New perspectives in treatment decision for integrated management of rectal cancer: multimodal research for multimodal treatments

Author: Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Abstract: Rectal cancer management improved results in the last thirty-five applying new integrated treatment options. Preoperative radiochemotherapy or radiotherapy alone joined to the modern surgery gaining significant improvement of outcomes. Nevertheless, a definitive conclusion about superiority of one on the other in term of survival and toxicity is still lacking, and further improvement is in general required and seems obtainable. The need for a wide sharing of the accumulated knowledge is represented by the consensus conferences that over the years summarizes the state of the art for the management of rectal cancer. One of the most promising opportunities comes from the attempt of characterization of the tumor heterogeneity. An always-increasing number of new parameters come from different sources including genomic, imaging, pathological features and many others. The need of new informatics technologies able to handle and continuously incorporate new inputs derived from the evidences is also imperative. The combined use of large shared databases and "learning models" could allow generating and rapidly testing new hypotheses, providing further survival improvement in the next years.
Published: 2014

36. Role of microRNA in response to ionizing radiations: evidences and potential impact on clinical practice for radiotherapy

Author: Cellini, Francesco, Morganti, Alessio Giuseppe, Genovesi, D, Silvestris, N, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco, Morganti, Alessio Giuseppe, Genovesi, D, Silvestris, N, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: MicroRNAs (miRNA) are small, non-coding, RNAs with gene expression regulator roles. As an important class of regulators of many cellular pathways, miRNAs are involved in many signaling pathways and DNA damage repair processes, affecting cellular radiosensitivity. Their role has led to interest in oncological implications to improve treatment results. MiRNAs represent a great opportunity to enhance the efficacy of radiotherapy treatments-they can be used to profile the radioresistance of tumors before radiotherapy, monitor their response throughout the treatment, thus helping to select intensification strategies, and also to define the final response to therapy along with risks of recurrence or metastatization. Even though many interesting studies support such potential, nowadays most studies on patient data are limited to experiments profiling tumor aggressiveness and response to radiotherapy. Moreover many studies report different although not conflicting results on the miRNAs evaluated for each tumor type. Without doubt, the clinical potential of such molecules for radiotherapy is striking and of high interest.
Published: 2014

37. Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma

Author: Cellini, Francesco, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco, Valentini, Vincenzo, Cellini, Francesco (ORCID:0000-0002-2145-2300), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: Oesophageal cancer is the sixth cause of cancer-related death worldwide. Nowadays radiochemotherapy (RTCT) plays a central role in the treatment settings of such disease. Evaluation of molecular targeted therapies is an attractive opportunity for the management of oesophageal, GEJ and gastric cancers to improve outcomes as happened for other primary tumours. Clinical trials focused on the potential of many molecular targeted agents included in CT schedules, but also on the possibility, efficacy and tolerance of their use combined with RT. This review will focus on the over 15 more promising agents studied in combination with RT for esophagogastric tumour, describing the mechanism and target of action, evidences and potential future role on over 50 trials evaluated. Mechanisms of action, studies and evidences about Human Epidermal Growth Factor type 2 Targeting Agents (one of the more promising), Epidermal Growth Factor's Receptor Inhibitors (nowadays showing a lower potential than expected), Vascular Endothelial Growth Factor Inhibitors, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor and other targeting agents are reviewed.
Published: 2014

38. Development of a modelling to correlate site and diameter of brain metastases with hippocampal sparing using volumetric modulated Arc therapy

Author: Chiesa, Silvia, Balducci, Mario, Azario, Luigi, Gaudino, Simona, Cellini, Francesco, Mattiucci, Gian Carlo, Colosimo, Cesare, Valentini, Vincenzo, Chiesa, Silvia (ORCID:0000-0003-0168-3459), Balducci, Mario (ORCID:0000-0003-0398-9726), Azario, Luigi (ORCID:0000-0001-8575-8627), Gaudino, Simona (ORCID:0000-0003-1681-4343), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Chiesa, Silvia, Balducci, Mario, Azario, Luigi, Gaudino, Simona, Cellini, Francesco, Mattiucci, Gian Carlo, Colosimo, Cesare, Valentini, Vincenzo, Chiesa, Silvia (ORCID:0000-0003-0168-3459), Balducci, Mario (ORCID:0000-0003-0398-9726), Azario, Luigi (ORCID:0000-0001-8575-8627), Gaudino, Simona (ORCID:0000-0003-1681-4343), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Colosimo, Cesare (ORCID:0000-0003-3800-3648), and Valentini, Vincenzo (ORCID:0000-0003-4637-6487)
Abstract: To correlate site and diameter of brain metastases with hippocampal sparing in patients treated by RapidArc (RA) technique on whole brain with simultaneously integrated boost (SIB).
Published: 2013

39. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review

Author: Morganti, Alessio Giuseppe, Di Castelnuovo, Augusto Filippo, Massaccesi, Mariangela, Cellini, Francesco, Cilla, Savino, Macchia, Gabriella, Forte, Paola, Buwenge, Milly, Digesu', Cinzia, Ferro, Milena, Picardi, Vincenzo, Caravatta, Luciana, Valentini, Vincenzo, Deodato, Francesco, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Deodato, Francesco (ORCID:0000-0003-1276-5070), Morganti, Alessio Giuseppe, Di Castelnuovo, Augusto Filippo, Massaccesi, Mariangela, Cellini, Francesco, Cilla, Savino, Macchia, Gabriella, Forte, Paola, Buwenge, Milly, Digesu', Cinzia, Ferro, Milena, Picardi, Vincenzo, Caravatta, Luciana, Valentini, Vincenzo, Deodato, Francesco, Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Deodato, Francesco (ORCID:0000-0003-1276-5070)
Abstract: The objective of this study was to establish the impact of three-dimensional conformal radiotherapy (3D-CRT) technique in post-operative radiotherapy of gastric cancer. A bibliographical research was performed using the PubMed. On the database, Search was carried out using Medical Subject Heading (MeSH) database; the algorithm for search was ''Radiotherapy" (MeSH) AND ''Stomach Neoplasms" (MeSH). Only planning comparative studies on conformal techniques vs standard techniques in post-operative radiotherapy of gastric cancer were included in the review process. We identified 185 papers, five of them fulfilling the inclusion criteria. A great inhomogeneity was observed regarding the analysed dosimetric end points. Three of the five studies reported a benefit in favour of 3D-CRT for target irradiation despite a minimal advantage in most cases. The liver was better spared from irradiation by the traditional technique in all studies. No univocal result was obtained for the right kidney: the traditional technique performed better in two studies, 3D-CRT yielded better results in two others, whereas in the fifth study, each technique was either better or worse according to the different considered end point. 3D-CRT, however, allowed for better sparing of the left kidney in four studies. There is no absolute reason to prefer 3D-CRT with multiple beams in every patient. It may be preferable to choose the technique based on individual patient characteristics. Because there is no proof of superiority for 3D-CRT, there is no absolute reason to exclude patients who are treated in centres equipped with only the two-dimensional technique from the potential benefit of post-operative chemoradiation.
Published: 2013

40. Current treatment of rectal cancer adapted to the individual patient.

Author: Cerezo, L, Ciria, Jp, Arbea, L, Liñán, O, Cafiero, S, Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Cerezo, L, Ciria, Jp, Arbea, L, Liñán, O, Cafiero, S, Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Abstract: Preoperative radiochemotherapy and total mesorectal excision surgery is a recommended standard therapy for patients with locally advanced rectal cancer. However, some subgroups of patients benefit more than others from this approach. In order to avoid long-term complications of radiation and chemotherapy, efforts are being made to subdivide T3N0 stage using advanced imaging techniques, and to analyze prognostic factors that help to define subgroup risk patients. Long-course radiochemotherapy has the potential of downsizing the tumor before surgery and may increase the chance of sphincter preservation in some patients. Short-course radiotherapy (SCRT), on the other hand, is a practical schedule that better suits patients with intermediated risk tumors, located far from the anal margin. SCRT is also increasingly being used among patients with disseminated disease, before resection of the rectal tumor. Improvements in radiation technique, such as keeping the irradiation target below S2/S3 junction, and the use of IMRT, can reduce the toxicity associated with radiation, specially long-term small bowel toxicity.
Published: 2013

41. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience

Author: Balducci, Mario, Chiesa, Silvia, Manfrida, Stefania, Rossi, Elisabetta, Za, Tommaso, Frascino, Vincenzo, De Bari, Berardino, Hohaus, Stefan, Cellini, Francesco, Mantini, Giovanna, D'Agostino, Giuseppe Roberto, Gambacorta, Maria Antonietta, Leone, Alessandra, Valentini, Vincenzo, De Stefano, Valerio, Balducci, Mario (ORCID:0000-0003-0398-9726), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Rossi, Elisabetta (ORCID:0000-0002-2677-2290), Hohaus, Stefan (ORCID:0000-0002-5534-7197), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Balducci, Mario, Chiesa, Silvia, Manfrida, Stefania, Rossi, Elisabetta, Za, Tommaso, Frascino, Vincenzo, De Bari, Berardino, Hohaus, Stefan, Cellini, Francesco, Mantini, Giovanna, D'Agostino, Giuseppe Roberto, Gambacorta, Maria Antonietta, Leone, Alessandra, Valentini, Vincenzo, De Stefano, Valerio, Balducci, Mario (ORCID:0000-0003-0398-9726), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Rossi, Elisabetta (ORCID:0000-0002-2677-2290), Hohaus, Stefan (ORCID:0000-0002-5534-7197), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and De Stefano, Valerio (ORCID:0000-0002-5178-5827)
Abstract: To evaluate the impact of radiotherapy on pain relief and on recalcification in patients with osteolytic lesions due to plasma cell neoplasm.
Published: 2011

42. Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms : Long-Term Experience.

Author: Balducci, Mario, Chiesa, Silvia, Manfrida, Stefania, Rossi, Elena, Za, Tommaso, Frascino, Vincenzo, De Bari, Berardino, Hohaus, Stefan, Cellini, Francesco, Mantini, Giovanna, D'Agostino, Gr, Gambacorta, Maria Antonietta, Leone, Antonio, Valentini, Vincenzo, De Stefano, Valerio, Balducci, Mario (ORCID:0000-0003-0398-9726), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Rossi, Elena (ORCID:0000-0002-7572-9379), Hohaus, Stefan (ORCID:0000-0002-5534-7197), Cellini, Francesco (ORCID:0000-0002-2145-2300), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Leone, Antonio (ORCID:0000-0003-3669-6321), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Balducci, Mario, Chiesa, Silvia, Manfrida, Stefania, Rossi, Elena, Za, Tommaso, Frascino, Vincenzo, De Bari, Berardino, Hohaus, Stefan, Cellini, Francesco, Mantini, Giovanna, D'Agostino, Gr, Gambacorta, Maria Antonietta, Leone, Antonio, Valentini, Vincenzo, De Stefano, Valerio, Balducci, Mario (ORCID:0000-0003-0398-9726), Chiesa, Silvia (ORCID:0000-0003-0168-3459), Rossi, Elena (ORCID:0000-0002-7572-9379), Hohaus, Stefan (ORCID:0000-0002-5534-7197), Cellini, Francesco (ORCID:0000-0002-2145-2300), Gambacorta, Maria Antonietta (ORCID:0000-0001-5455-8737), Leone, Antonio (ORCID:0000-0003-3669-6321), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and De Stefano, Valerio (ORCID:0000-0002-5178-5827)
Abstract: PURPOSE: To evaluate the impact of radiotherapy on pain relief and on recalcification in patients with osteolytic lesions due to plasma cell neoplasm. PATIENTS AND METHODS: Pain relief was evaluated according to a 0-10 verbal numerical rating scale (NRS) and recalcification was measured using radiological imaging. RESULTS: From 1996-2007, 52 patients were treated (Table 1). Median total dose was 38 Gy (range, 16-50 Gy). Pain be-fore radiotherapy was reported by 45 of 52 (86.5%) patients (Table 2) as being severe (8 ≤ NRS ≤ 10) in 5 (11%), moderate (5 ≤ NRS ≤ 7) in 27 (60%), and mild in 13 (29%). Pain relief was achieved in 41 of 45 patients (91%): complete relief was obtained in 21 (51.2%) and partial relief in 20 patients (48.8%); patients with severe pain experienced resolution and none present-ed an increase of pain. Drugs reduction/suspension was achieved in 7 of the 21 patients with complete response. Of 42 patients evaluable for recalcification (Table 3), 21 (50%) presented a radiological response, which was identified as complete in 16 (38%). CONCLUSION: Our data confirm the effectiveness of radiotherapy for pain relief, including a reduction in drug intake, and on recalcification, thus, supporting its use in a multidisciplinary approach.
Published: 2011

43. Surgery: neoadjuvant chemoradiation and sphincter preservation

Author: Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Published: 2009

44. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis.

Author: Valentini, Vincenzo, Cellini, Francesco, Minsky, Bd, Mattiucci, Gian Carlo, Balducci, Mario, D'Agostino, Giuseppe Roberto, D'Angelo, Elisa, Dinapoli, Nicola, Nicolotti, Nicola, Valentini, Chiara, La Torre, Giuseppe, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), Balducci, Mario (ORCID:0000-0003-0398-9726), Valentini, Vincenzo, Cellini, Francesco, Minsky, Bd, Mattiucci, Gian Carlo, Balducci, Mario, D'Agostino, Giuseppe Roberto, D'Angelo, Elisa, Dinapoli, Nicola, Nicolotti, Nicola, Valentini, Chiara, La Torre, Giuseppe, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Mattiucci, Gian Carlo (ORCID:0000-0001-6500-0413), and Balducci, Mario (ORCID:0000-0003-0398-9726)
Abstract: A systematic review and meta-analysis was performed to assess the impact of radiotherapy on both 3- and 5-year survival in patients with resectable gastric cancer. METHODS: Randomized Clinical Trials (RCTs) in which radiotherapy, (preoperative, postoperative and/or intraoperative), was compared with surgery alone or surgery plus chemotherapy in resectable gastric cancer were identified by searching web-based databases and supplemented by manual examination of reference lists. Meta-analysis was performed using Risk Ratios (RRs). Random or fixed effects models were used to combine data. The methodological quality was evaluated by Chalmers' score. RESULTS: Radiotherapy had a significant impact on 5-year survival. Using an intent to treat (ITT) and a Per Protocol (PP) analysis, the overall 5-year RR was 1.26 (95% CI: 1.08-1.48; NNT=17) and 1.31 (95% CI: 1.04-1.66; NNT=13), respectively. Although the quality of the studies was variable, the data were consistent and no clear publication bias was found. CONCLUSION: This meta-analysis showed a statistically significant 5-year survival benefit with the addition of radiotherapy in patients with resectable gastric cancer. Radiotherapy remains a standard component in the treatment of resectable gastric cancer and new RCTs need to address the impact of new conformal radiotherapy technologies.
Published: 2009

45. Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection.

Author: D'Angelillo, Rolando Maria, Trodella, Lucio, Ramella, Sara, Cellini, Numa, Balducci, Mario, Mantini, Giovanna, Cellini, Francesco, Ciresa, Marzia, Fiore, Michele, Evoli, Amelia, Sterzi, Silvia, Russo, Patrizia, Grozio, Alessia, Cesario, Alfredo, Granone, Pierluigi, Balducci, Mario (ORCID:0000-0003-0398-9726), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Cellini, Francesco (ORCID:0000-0002-2145-2300), Evoli, Amelia (ORCID:0000-0003-0282-8787), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Granone, Pierluigi (ORCID:0000-0002-8826-3045), D'Angelillo, Rolando Maria, Trodella, Lucio, Ramella, Sara, Cellini, Numa, Balducci, Mario, Mantini, Giovanna, Cellini, Francesco, Ciresa, Marzia, Fiore, Michele, Evoli, Amelia, Sterzi, Silvia, Russo, Patrizia, Grozio, Alessia, Cesario, Alfredo, Granone, Pierluigi, Balducci, Mario (ORCID:0000-0003-0398-9726), Mantini, Giovanna (ORCID:0000-0001-5303-4499), Cellini, Francesco (ORCID:0000-0002-2145-2300), Evoli, Amelia (ORCID:0000-0003-0282-8787), Cesario, Alfredo (ORCID:0000-0003-4687-0709), and Granone, Pierluigi (ORCID:0000-0002-8826-3045)
Abstract: PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TETs) (i.e., thymomas and thymic squamous cell carcinoma) and to define the prognostic classes according to the Masaoka and World Health Organization histologic classification systems. METHODS AND MATERIALS: Primary surgery was the mainstay of therapy. Extended thymectomy was performed in all cases. The cases were primarily staged according to the Masaoka system. Adjuvant radiotherapy was given to patients diagnosed with Masaoka Stage II, III, and IVA TET. Adjuvant chemotherapy was administered in selected cases. RESULTS: We reviewed the records of 120 patients with TETs, with a mean follow-up of 13.8 years. Of the 120 patients, 98 (81.6%) received adjuvant radiotherapy. Of these 98 patients, Grade 1-2 pulmonary or esophageal toxicity was acute in 12 (12.2%) and late in 8 (8.2%). The median overall survival was 21.6 years. Of the 120 patients, 106 were rediagnosed and reclassified according to the World Health Organization system, and the survival rate was correlated with it. Three different prognostic classes were defined: favorable, Masaoka Stage I and histologic grade A, AB, B1, B2 or Masaoka Stage II and histologic grade A, AB, B1; unfavorable, Stage IV disease or histologic grade C or Stage III and histologic grade B3; intermediate, all other combinations. The 10- and 20-year survival rate was 95% and 81% for the favorable group, 90% and 65% for the intermediate group, and 50% and 0% for the unfavorable group, respectively. Local recurrence, distant recurrence, and tumor-related deaths were also evaluated. CONCLUSION: The analysis of our experience singled out three novel prognostic classes and the assessment of risk identified treatment selection criteria.
Published: 2008
Full Text: View/download PDF

46. Radiotherapy in gastric cancer: a systematic review of literature and new perspectives.

Author: Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo, Cellini, Francesco, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Abstract: N/A
Published: 2007

47. Combined treatments in gastric cancer: radiotherapy.

Author: Valentini, Vincenzo, Cellini, Francesco, D'Angelillo, Rolando Maria, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Cellini, Francesco (ORCID:0000-0002-2145-2300), Valentini, Vincenzo, Cellini, Francesco, D'Angelillo, Rolando Maria, Valentini, Vincenzo (ORCID:0000-0003-4637-6487), and Cellini, Francesco (ORCID:0000-0002-2145-2300)
Abstract: N/a
Published: 2003

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

47 results on '"Cellini, Francesco (ORCID:0000-0002-2145-2300)"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources